Positive response to oral chemoendocrine combination therapy using 5"-deoxy-5-fluorouridine for locally advanced breast cancer with carcinomatous pleurisy: report of a case.
A 60-year-old postmenopausal woman presented with an ulcerating and bleeding tumor in her right breast. On physical examination, the tumor was found mainly in the D area of the right breast, and was associated with ulceration and thoracic rigidity. Chest X-ray showed a pleural effusion in her right chest and a computed tomography scan after thoracentesis showed multiple bilateral pleural nodules. Thus, a diagnosis of unresectable advanced breast cancer (T4cN2M1b, PLE) was made. She was given oral 5"-deoxy-5-fluorouridine (5"-DFUR) with medroxyprogesterone acetate, followed by tamoxifen, without any severe adverse reactions, and was subsequently followed up as an outpatient. Her tumor gradually decreased in size, the thoracic rigidity disappeared, and the pleural dissemination and effusion resolved. Thereafter, a radical mastectomy was performed and histologically, the tumor was Grade 1a. She had no signs of recurrence or metastasis 14 months postoperatively. Therefore, oral chemoendocrine combination therapy with 5"-DFUR resulted in a favorable quality of life, there were no severe adverse reactions, and the patient was able to be managed as an outpatient.
Suzuki
On
O
Department of Surgery, Obihiro Kousei Hospital, W6, S8, Obihiro, 080-0016, Japan.
Sekishita
Yoshiaki
Y
Shiono
Tuneo
T
Kondo
Satoshi
S
Kato
Hiroyuki
H
D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D004703:Endocrine System / Q000187:drug effects*; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000209:etiology; D011788:Quality of Life; D013629:Tamoxifen / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D005467:Floxuridine; D013629:Tamoxifen; D017258:Medroxyprogesterone Acetate; C025034:doxifluridine